NanoEntek, Inc. (NanoenTek) aksje

NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company also provides digital healthcare services integrating artificial intelligence and big data technologies. The company was founded in 1987 and is headquartered in Seoul, South Korea.